Thymoma: an integrated clinicopathological and immunohistochemical study

Area of Science:

• Oncology
• Pathology
• Immunohistochemistry

Background:

• Thymomas are neoplasms of the thymus gland with varying clinical behavior.
• Accurate staging and classification are crucial for prognosis and treatment.
• Immunohistochemical markers can help elucidate tumor biology and aid in diagnosis.

Purpose of the Study:

• To review the clinicopathological features of thymomas.
• To investigate the antigenic profiles of thymomas using monoclonal antibodies.
• To correlate antigenic expression with tumor stage and histological type.

Main Methods:

• Review of 32 thymoma cases with clinicopathological data.
• Tumor staging based on the degree of invasion.
• Immunohistochemical analysis using antibodies for cytokeratins (CAM 5.2, DAKO-CK1), HNK-1 (Leu 7), and HLA-DR (TAL-IB5).

Main Results:

• Stage I thymomas were predominantly spindle cell (SC) or predominantly lymphocytic (PL) types.
• Predominantly epithelial (PE) tumors were invasive (Stage II) or widely spread (Stage III).
• Cytokeratin expression varied; CAM 5.2 highlighted peripheral cells and tubulo-cystic areas, while DAKO-CK1 indicated medullary differentiation.
• HNK-1 expression increased with tumor invasiveness, particularly in PE and mixed (M) types.
• TAL-IB5 expression decreased in more invasive thymomas.
• Focal medullary differentiation suggests a common origin for thymic epithelial cells, challenging sub-classification into cortical/medullary types.

Conclusions:

• Immunohistochemistry is a valuable tool to complement clinical and macroscopic findings in assessing thymoma malignancy.
• The antigenic profiles of thymomas correlate with their stage and histological type.
• Evidence suggests a unified origin for thymic epithelial cells, questioning distinct cortical and medullary tumor classifications.